NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Naproxen Sodium And Diphenhydramine Hydrochloride patents expire, and when can generic versions of Naproxen Sodium And Diphenhydramine Hydrochloride launch?
Naproxen Sodium And Diphenhydramine Hydrochloride is a drug marketed by Amneal Pharms Co, Corepharma, Granules, P And L, and Perrigo R And D. and is included in five NDAs.
The generic ingredient in NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE is diphenhydramine hydrochloride; naproxen sodium. There are twenty-three drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride; naproxen sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE?
- What are the global sales for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE?
- What is Average Wholesale Price for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE?
Summary for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 21 |
| Clinical Trials: | 9 |
| DailyMed Link: | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ciusss de L'Est de l'Île de Montréal | N/A |
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Alphacait, LLC | Phase 2 |
See all NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE clinical trials
Pharmacology for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
| Drug Class | Histamine-1 Receptor Antagonist Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors Histamine H1 Receptor Antagonists |
